Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-trace').style.display = (document.getElementById('cakeErr67f3e738a04de-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f3e738a04de-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-code').style.display = (document.getElementById('cakeErr67f3e738a04de-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-context').style.display = (document.getElementById('cakeErr67f3e738a04de-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f3e738a04de-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f3e738a04de-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 8849,
		&#039;title&#039; =&gt; &#039;UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The United Nations
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;
&lt;br /&gt;
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;
&lt;br /&gt;
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;
&lt;br /&gt;
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;
&lt;br /&gt;
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;
&lt;br /&gt;
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&amp;Cr=hiv&amp;Cr1=aids&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 8951,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 8849,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The United Nations


&amp;nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p&gt;-The United Nations&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;&lt;br /&gt;The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;&lt;br /&gt;The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;&lt;br /&gt;Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;&lt;br /&gt;Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;&lt;br /&gt;The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 8849,
	&#039;title&#039; =&gt; &#039;UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The United Nations
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;
&lt;br /&gt;
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;
&lt;br /&gt;
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;
&lt;br /&gt;
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;
&lt;br /&gt;
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;
&lt;br /&gt;
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&amp;Cr=hiv&amp;Cr1=aids&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 8951,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 8849
$metaTitle = &#039;LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;
-The United Nations


&amp;nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...&#039;
$disp = &#039;&lt;p&gt;-The United Nations&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;&lt;br /&gt;The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;&lt;br /&gt;The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;&lt;br /&gt;Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;&lt;br /&gt;Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;&lt;br /&gt;The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries | Im4change.org</title>
    <meta name="description" content="
-The United Nations


&nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>UN welcomes pact to improve access of patented AIDS drugs in poor countries</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p>-The United Nations</p><p>&nbsp;</p><div align="justify">The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br /><br />The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br /><br />The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br /><br />Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br /><br />Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br /><br />&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br /><br />&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br /><br />The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-trace').style.display = (document.getElementById('cakeErr67f3e738a04de-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f3e738a04de-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-code').style.display = (document.getElementById('cakeErr67f3e738a04de-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-context').style.display = (document.getElementById('cakeErr67f3e738a04de-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f3e738a04de-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f3e738a04de-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 8849,
		&#039;title&#039; =&gt; &#039;UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The United Nations
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;
&lt;br /&gt;
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;
&lt;br /&gt;
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;
&lt;br /&gt;
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;
&lt;br /&gt;
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;
&lt;br /&gt;
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&amp;Cr=hiv&amp;Cr1=aids&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 8951,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 8849,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The United Nations


&amp;nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p&gt;-The United Nations&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;&lt;br /&gt;The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;&lt;br /&gt;The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;&lt;br /&gt;Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;&lt;br /&gt;Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;&lt;br /&gt;The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 8849,
	&#039;title&#039; =&gt; &#039;UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The United Nations
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;
&lt;br /&gt;
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;
&lt;br /&gt;
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;
&lt;br /&gt;
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;
&lt;br /&gt;
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;
&lt;br /&gt;
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&amp;Cr=hiv&amp;Cr1=aids&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 8951,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 8849
$metaTitle = &#039;LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;
-The United Nations


&amp;nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...&#039;
$disp = &#039;&lt;p&gt;-The United Nations&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;&lt;br /&gt;The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;&lt;br /&gt;The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;&lt;br /&gt;Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;&lt;br /&gt;Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;&lt;br /&gt;The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries | Im4change.org</title>
    <meta name="description" content="
-The United Nations


&nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>UN welcomes pact to improve access of patented AIDS drugs in poor countries</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p>-The United Nations</p><p>&nbsp;</p><div align="justify">The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br /><br />The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br /><br />The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br /><br />Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br /><br />Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br /><br />&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br /><br />&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br /><br />The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-trace').style.display = (document.getElementById('cakeErr67f3e738a04de-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f3e738a04de-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-code').style.display = (document.getElementById('cakeErr67f3e738a04de-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3e738a04de-context').style.display = (document.getElementById('cakeErr67f3e738a04de-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f3e738a04de-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f3e738a04de-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 8849,
		&#039;title&#039; =&gt; &#039;UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The United Nations
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;
&lt;br /&gt;
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;
&lt;br /&gt;
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;
&lt;br /&gt;
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;
&lt;br /&gt;
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;
&lt;br /&gt;
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&amp;Cr=hiv&amp;Cr1=aids&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 8951,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 8849,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The United Nations


&amp;nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p&gt;-The United Nations&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;&lt;br /&gt;The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;&lt;br /&gt;The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;&lt;br /&gt;Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;&lt;br /&gt;Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;&lt;br /&gt;The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 8849,
	&#039;title&#039; =&gt; &#039;UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The United Nations
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;
&lt;br /&gt;
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;
&lt;br /&gt;
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;
&lt;br /&gt;
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;
&lt;br /&gt;
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;
&lt;br /&gt;
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&amp;Cr=hiv&amp;Cr1=aids&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 8951,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 8849
$metaTitle = &#039;LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;
-The United Nations


&amp;nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...&#039;
$disp = &#039;&lt;p&gt;-The United Nations&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.&lt;br /&gt;&lt;br /&gt;The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.&lt;br /&gt;&lt;br /&gt;The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.&lt;br /&gt;&lt;br /&gt;Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &amp;ldquo;Quad.&amp;rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.&lt;br /&gt;&lt;br /&gt;Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&amp;rdquo; said Michel Sidib&amp;eacute;, the Executive Director of UNAIDS.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;I hope today&amp;rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&amp;rdquo; he added.&lt;br /&gt;&lt;br /&gt;The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries | Im4change.org</title>
    <meta name="description" content="
-The United Nations


&nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>UN welcomes pact to improve access of patented AIDS drugs in poor countries</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p>-The United Nations</p><p>&nbsp;</p><div align="justify">The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br /><br />The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br /><br />The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br /><br />Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br /><br />Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br /><br />&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br /><br />&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br /><br />The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 8849,
		'title' => 'UN welcomes pact to improve access of patented AIDS drugs in poor countries',
		'subheading' => '',
		'description' => '<p>
-The United Nations
</p>
<p>
&nbsp;
</p>
<div align="justify">
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br />
<br />
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br />
<br />
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br />
<br />
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br />
<br />
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br />
<br />
&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br />
<br />
&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br />
<br />
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
</div>',
		'credit_writer' => 'The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&Cr=hiv&Cr1=aids',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 8951,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 8849,
	'metaTitle' => 'LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries',
	'metaKeywords' => 'Health',
	'metaDesc' => '
-The United Nations


&nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...',
	'disp' => '<p>-The United Nations</p><p>&nbsp;</p><div align="justify">The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br /><br />The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br /><br />The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br /><br />Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br /><br />Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br /><br />&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br /><br />&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br /><br />The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 8849,
	'title' => 'UN welcomes pact to improve access of patented AIDS drugs in poor countries',
	'subheading' => '',
	'description' => '<p>
-The United Nations
</p>
<p>
&nbsp;
</p>
<div align="justify">
The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br />
<br />
The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br />
<br />
The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br />
<br />
Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br />
<br />
Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br />
<br />
&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br />
<br />
&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br />
<br />
The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.
</div>',
	'credit_writer' => 'The United Nations, 12 July, 2011, http://www.un.org/apps/news/story.asp?NewsID=39018&Cr=hiv&Cr1=aids',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'un-welcomes-pact-to-improve-access-of-patented-aids-drugs-in-poor-countries-8951',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 8951,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 8849
$metaTitle = 'LATEST NEWS UPDATES | UN welcomes pact to improve access of patented AIDS drugs in poor countries'
$metaKeywords = 'Health'
$metaDesc = '
-The United Nations


&nbsp;


The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.

The...'
$disp = '<p>-The United Nations</p><p>&nbsp;</p><div align="justify">The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries.<br /><br />The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV.<br /><br />The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries.<br /><br />Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the &ldquo;Quad.&rdquo; Cobicistat, elvitegravir and Quad are still in clinical development.<br /><br />Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms.<br /><br />&ldquo;This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,&rdquo; said Michel Sidib&eacute;, the Executive Director of UNAIDS.<br /><br />&ldquo;I hope today&rsquo;s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,&rdquo; he added.<br /><br />The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

UN welcomes pact to improve access of patented AIDS drugs in poor countries

-The United Nations   The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries. The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning point for future private sector collaboration in sharing innovation to advance the global response to HIV. The Medicines Patent Pool negotiates with patent holders to share their intellectual property with the Pool, then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in poorer countries. Under the agreement, Gilead will share intellectual property on a range of medicines to treat HIV/AIDS. The agreement will allow for the production of the medicines tenofovir, emtricitabine, cobicistat, and elvitegravir as well as a combination of the products in a single pill known as the “Quad.” Cobicistat, elvitegravir and Quad are still in clinical development. Companies interested in producing generic versions of the medicines for developing countries will be able to approach the Patent Pool to negotiate licensing terms. “This agreement between the Medicines Patent Pool and Gilead signals a new era in the response to HIV with private and public sectors working hand in hand for the best interests of public health,” said Michel Sidibé, the Executive Director of UNAIDS. “I hope today’s announcement will inspire other pharmaceutical companies to follow suit to share intellectual property and innovation to make new technological advances in HIV treatment available sooner to the people that need them most,” he added. The agreement is especially significant because tenofovir is one of the first-line medicines for HIV/AIDS recommended for use by the UN World Health Organization (WHO), according to guidelines released last year. Under the new agreement, tenofovir will also be licensed for use to treat Hepatitis B, a common and serious co-infection of HIV.